Merck boosts bioprocessing capabilities with MAST platform from Lonza
The MAST platform provides real-time process information, reduces the process development time by half, and lowers costs
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Apr 22
The MAST platform provides real-time process information, reduces the process development time by half, and lowers costs
28 Mar 22
The new manufacturing facility at Kent Science Park is designed to support the manufacture of regulatory approved cannabis-based…
08 Mar 22
The new site will use new technologies to enhance the efficiency and capability to produce a wide range…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Feb 22
Thermo Fisher will provide dedicated capacity to scale-up the production of Moderna’s Covid-19 vaccine, and other potential mRNA…
15 Feb 22
The agreement follows the US government’s initial deal for 700,000 doses of Evusheld, which are already being administered…
31 Jan 22
The new facility will use advanced technology to produce parenteral products and devices and expand Lilly’s manufacturing capacity
16 Dec 21
The new facility would create more than 50 new jobs in the coming years, in addition to around…
15 Dec 21
The investment is expected to expand Novo Nordisk’s production capacity from active pharmaceutical ingredients (API) to assembly and…
07 Dec 21
Thermo Fisher will dedicate its manufacturing facility in Ontario, Canada to make Merck’s molnupiravir and distribute the drug…
23 Nov 21
The new 19,000m2 R&D facility that represents £1bn investment will feature the most advanced robotics, high-throughput screening and…